Asset Details
Do you wish to reserve the book?
Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion
Do you wish to request the book?
Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion
2016
Overview
Transarterial chemoembolization with Lipiodol (Lipiodol TACE), also called conventional TACE, was developed in the early 1980s and widely adopted worldwide after randomized control trials and meta-analysis demonstrated superiority of Lipiodol TACE to best supportive care. Presently, there is no level one evidence that other TACE techniques are superior to Lipiodol TACE for intermediate stage hepatocellular carcinoma (HCC), which includes patients with preserved liver function and nonsurgical large or multinodular HCC without distant metastases. In addition, TACE is part of the treatment for progressive or symptomatic liver metastases from gastroenteropancreatic neuroendocrine tumors. When injected into the hepatic artery, Lipiodol has the unique property of selective uptake and retention in hyperarterialyzed liver tumors. Lipiodol/drug emulsion followed by particle embolization has been demonstrated to improve the pharmacokinetic of the drug and tumor response. Radio opacity of Lipiodol helps to monitor treatment delivery, with retention of Lipiodol serving as an imaging biomarker for tumor response. For 30 years, Lipiodol TACE has been inconsistently referenced in many publications with various levels of details for the method of preparation and administration, with reported progressive outcomes following improvements in the technique and the devices used to deliver the treatment and better patient selection. Consequently, there is no consensus on the standard method of TACE regarding the use of anticancer agents, embolic material, technical details, and the treatment schedule. In order to develop an internationally validated technical recommendation to standardize the Lipiodol TACE procedure, a worldwide panel of experts participated in a consensus meeting held on May 10, 2014 .
Publisher
Springer US,Springer Nature B.V
Subject
Antineoplastic Agents - administration & dosage
/ ARTERIES
/ Carcinoma, Hepatocellular - diagnostic imaging
/ Carcinoma, Hepatocellular - therapy
/ Chemoembolization, Therapeutic - methods
/ DRUGS
/ Ethiodized Oil - administration & dosage
/ Gastrointestinal Neoplasms - diagnostic imaging
/ Gastrointestinal Neoplasms - therapy
/ Humans
/ Imaging
/ LIPIODOL
/ LIVER
/ Liver Neoplasms - diagnostic imaging
/ Medicine
/ Neuroendocrine Tumors - diagnostic imaging
/ Neuroendocrine Tumors - therapy
/ PATIENTS
/ RADIOLOGY AND NUCLEAR MEDICINE
/ Review
